OBJECTIVES: The main objetive was to evaluate the cost reduction by introduction of equivalent therapeutic program after the accord in the Central Pharmaceutical Commission in Extremadura. METHODS: Retrospective observational study between March 2013 and March 2014. We agree that micafungin was the preferential echinocandin for the same indication. Caspofungin was restricted for empiric treatment of fungal infection in patients with fever and neutropenia and  Anidulafungin was used in patients with hepatic dysfunction. To quantify the avoided costs we extracted consumption data and costs of antifungals from the Pharmacy Department Multibase v.3. Program (Dominion) and compared them with the same period the previous year. RESULTS: Regarding avoided costs for the period of the study, echinocandins costs were reduced by 353.965 euros, a 24,35 % less than previous year. In the first period, the echinocandin most used was caspofungin (51,23%) because the prescription wasn´t restricted and the physician could use anyone. In the second period, we observed a 31,63%  increase in use in micafungin, the echinocandin that we evaluated the most efficient in our protocol. The use of caspofungin and anidulafungin decreased a 11,92% and 19,71% respectively. These use involved a decrease in cost too, 255.836 and 254.896 euros less about anidulafungin and caspofungin use respectively. These results are consistent with the recommendations contained in our program (first line use of micafungin in nonimmunosuppressed patients with candida infection). CONCLUSIONS: Our therapeutic program compliance was good at our hospitals, resulting in a significant decrease in echinocandins expenses. Maybe, the implementation of these  type of programs in the management of high-cost drugs resulted in significant cost reductions and therefore in a more rational use of healthcare budgets.